Summit Therapeutics Statistics
Total Valuation
SMMT has a market cap or net worth of $11.46 billion. The enterprise value is $10.89 billion.
| Market Cap | 11.46B |
| Enterprise Value | 10.89B |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SMMT has 776.16 million shares outstanding. The number of shares has increased by 4.05% in one year.
| Current Share Class | 776.16M |
| Shares Outstanding | 776.16M |
| Shares Change (YoY) | +4.05% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 78.52% |
| Owned by Institutions (%) | 15.57% |
| Float | 134.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 1,071.29 |
| PB Ratio | 20.99 |
| P/TBV Ratio | 21.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.41, with a Debt / Equity ratio of 0.04.
| Current Ratio | 7.41 |
| Quick Ratio | 7.19 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -270.95% and return on invested capital (ROIC) is -166.73%.
| Return on Equity (ROE) | -270.95% |
| Return on Assets (ROA) | -148.15% |
| Return on Invested Capital (ROIC) | -166.73% |
| Return on Capital Employed (ROCE) | -216.58% |
| Weighted Average Cost of Capital (WACC) | -2.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.55M |
| Employee Count | 265 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.49% in the last 52 weeks. The beta is -1.31, so SMMT's price volatility has been lower than the market average.
| Beta (5Y) | -1.31 |
| 52-Week Price Change | -24.49% |
| 50-Day Moving Average | 18.90 |
| 200-Day Moving Average | 18.48 |
| Relative Strength Index (RSI) | 35.98 |
| Average Volume (20 Days) | 5,162,758 |
Short Selling Information
The latest short interest is 29.82 million, so 22.11% of the outstanding shares have been sold short.
| Short Interest | 29.82M |
| Short Previous Month | 29.19M |
| Short % of Shares Out | 22.11% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.22B |
| Pretax Income | -1.21B |
| Net Income | -1.21B |
| EBITDA | -1.22B |
| EBIT | -1.22B |
| Earnings Per Share (EPS) | -$1.59 |
Balance Sheet
The company has $598.73 million in cash and $20.04 million in debt, with a net cash position of $578.69 million or $0.75 per share.
| Cash & Cash Equivalents | 598.73M |
| Total Debt | 20.04M |
| Net Cash | 578.69M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 545.93M |
| Book Value Per Share | 0.70 |
| Working Capital | 533.33M |
Cash Flow
In the last 12 months, operating cash flow was -$384.05 million and capital expenditures -$480,000, giving a free cash flow of -$384.53 million.
| Operating Cash Flow | -384.05M |
| Capital Expenditures | -480,000 |
| Depreciation & Amortization | 165,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -384.53M |
| FCF Per Share | -$0.50 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SMMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.05% |
| Shareholder Yield | -4.05% |
| Earnings Yield | -10.52% |
| FCF Yield | -3.35% |
Analyst Forecast
The average price target for SMMT is $28.42, which is 92.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.42 |
| Price Target Difference | 92.42% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |